Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.

<h4>Background</h4>Non-cystic fibrosis bronchiectasis (NCFBE) is a disease that exhibits dilatation of airways, airflow obstruction, persistent cough, excessive sputum production, and refractory respiratory infections. NCFBE exhibits clinical and pathological manifestations similar to ke...

Full description

Saved in:
Bibliographic Details
Main Authors: Colin E Swenson, William R Hunt, Candela Manfredi, Diana J Beltran, Jeong S Hong, Brian R Davis, Shingo Suzuki, Cristina Barillá, Andras Rab, Cynthia Chico, Joy Dangerfield, Ashleigh Streby, Erin Barton, Elizabeth M Cox, Arlene A Stecenko, Adrianna Westbrook, Rebecca Kapolka, Eric J Sorscher
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0316721
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pone.0316721

Similar Items